Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01733147 · ClinicalTrials.gov registry record · Phase 4
Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids
A Phase 4 study of Obesity and Barrett's Esophagus, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT01733147: Completed Phase 4 study of Obesity and Barrett's Esophagus, sponsored by Mayo Clinic.
NCT01733147 is a Phase 4 study of Obesity and Barrett's Esophagus that has completed, run by Mayo Clinic. The registered enrollment target is 60 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01733147, a Phase 4 study of Obesity and Barrett's Esophagus, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to understand the effect of dietary omega-3 fats in decreasing tissue inflammation in Barrett's esophagus.
Primary Outcome
Percent change from baseline to 6 months in serum prostaglandin E2 (PGE2) level obtained from blood draw
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Omega-3 polyunsaturated fatty acids
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2012-11 |
| Est. Completion | 2018-09-12 |
| Phase | Phase 4 |
What the finished NCT01733147 record still lists
NCT01733147 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01733147 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT01733147 about?
NCT01733147 is a clinical study titled "Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids". This study is being done to understand the effect of dietary omega-3 fats in decreasing tissue inflammation in Barrett's esophagus.
What is the current status of trial NCT01733147?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2012-11. Estimated completion is 2018-09-12.
What conditions does trial NCT01733147 study?
This clinical trial studies the following conditions: Obesity, Barrett's Esophagus.
What interventions are being tested in trial NCT01733147?
The interventions under investigation include: Placebo (DRUG), Omega-3 polyunsaturated fatty acids (DRUG).
Who is sponsoring clinical trial NCT01733147?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01733147 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01733147's enrollment target sits among peer trials
60 642nd of 1053 higher than 374 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia